Medpace/$MEDP

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX

About Medpace

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Ticker

$MEDP
Primary listing

Industry

Life Sciences Tools & Services

Employees

5,900

ISIN

US58506Q1094

Medpace Metrics

BasicAdvanced
$8.8B
23.44
$13.09
1.46
-

What the Analysts think about Medpace

Analyst ratings (Buy, Hold, Sell) for Medpace stock.

Bulls say / Bears say

Medpace reported Q1 2025 earnings of $3.67 per share, surpassing analyst expectations of $3.06, indicating strong financial performance. (Benzinga)
The company achieved a 9.3% year-over-year revenue increase in Q1 2025, reaching $558.57 million, showcasing robust growth. (TradingView News)
Medpace's backlog stood at approximately $2.85 billion at the end of Q1 2025, reflecting a strong pipeline of future projects. (Benzinga)
New business awards in Q1 2025 totaled $500 million, an 18.8% decline year-over-year, suggesting potential challenges in securing new contracts. (Benzinga)
Leerink Partners initiated coverage with a 'Market Perform' rating, citing concerns over elevated cancellation rates and a slowdown in new clinical trial starts due to reduced biotech funding post-COVID. (Nasdaq)
Medpace's stock has declined approximately 10.8% year-to-date as of April 2025, underperforming the S&P 500's decline of 10.2%, indicating potential investor concerns. (Finviz)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.

Medpace Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Medpace Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MEDP

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs